Yajie Liu | Cardiac Imaging | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Yajie Liu | Cardiac Imaging | Best Researcher Award

Peking University Shenzhen Hospital | China

Author Profile:

Scopus

Orcid

🌟Prof. Dr. Yajie Liu – A Pioneer in Radiation Oncology & Cancer Research Excellence

🎓 EARLY ACADEMIC PURSUITS

Dr. Yajie Liu began her medical journey with a Bachelor of Medicine (1985–1990) from Norman Bethune University of Medical Sciences. Driven by a deep interest in oncology, she completed her Master's degree in Oncology (1993–1996) from Harbin Medical University, followed by a prestigious Ph.D. in Oncology (1998–2001) at the Peking Union Medical College.

To expand her global medical perspective, she completed a Visiting Scholar Fellowship in Radiation Oncology at Chonnam National University Hospital in South Korea in 2010.

🏥 PROFESSIONAL ENDEAVORS

Dr. Liu's medical career spans over three decades of dedicated clinical service and leadership:

  • 1990–1992: Resident Physician, ENT, First Workers' Hospital of Liaohe Petroleum Exploration Bureau

  • 1992–1998: Resident & Attending Physician, Radiation Oncology, The Third Affiliated Hospital of Harbin Medical University

  • 2001–2017: Progressed from Attending to Chief Physician and Deputy Director at Shenzhen People’s Hospital

  • 2017–Present: Chief Physician and Director, Department of Radiation Oncology, Peking University Shenzhen Hospital

Her ascent to leadership reflects a consistent trajectory of clinical excellence and patient-centered care in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC IMAGING

Dr. Liu has led and co-led numerous research projects focused on:

  • Radiosensitization in Cancer Therapy

  • Hyperthermia and Serum Biomarkers

  • Radiation-Induced Brain Injury

  • Gene Assays for Breast Cancer Prognosis

  • Advanced Radiotherapy Strategies for Rectal and Colorectal Cancer

She has actively participated in national-level research, contributing to the Ministry of Science & Technology's high-impact projects on biomarkers and innovative radiotherapy techniques.

💡 RESEARCH FUNDING & PROJECT LEADERSHIP

As Principal Investigator (PI):

  • Shenzhen Science & Technology Bureau (4 Projects)

  • Shenzhen Health Commission (1 Project)

  • International Collaboration Grant (¥500K)

These funded projects demonstrate her innovative approach in blending clinical insight with technological advancement, especially in plasma therapy and hypoxic tumor sensitization.

🌐 PROFESSIONAL LEADERSHIP & ACADEMIC SERVICE

Dr. Liu holds key roles in multiple national and regional medical bodies:

  • Standing Committee Member, CRTOG

  • Committee Member, Radiotherapy Branch, Chinese Medical Doctor Association

  • Vice Chair, Lung Cancer Committee, Guangdong Women Doctors’ Association

  • Director, Radiotherapy Branch, Shenzhen Anti-Cancer Association

  • Council Member, Jiusan Society Shenzhen Chapter

Her positions reflect widespread recognition of her expertise and leadership in oncology.

📚 ACADEMIC CITES & COLLABORATIONS

While specific citation metrics are not provided here, Dr. Liu’s work on biomarkers, 21-gene assays, radiation injury, and colorectal cancer radiosensitization has contributed to national and international collaborations, significantly enriching the literature in radiation oncology.

🌍 IMPACT AND INFLUENCE

Dr. Liu's multidisciplinary research has influenced clinical protocols, improved patient outcomes, and inspired young oncologists across China. Her work on low-temperature plasma in radiosensitization reflects her commitment to cutting-edge translational oncology.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yajie Liu's legacy is marked by:

  • Pioneering radiotherapy techniques

  • Mentoring future oncology leaders

  • Driving forward international research collaborations

Her future direction is expected to focus on precision oncology, AI-guided radiotherapy planning, and expanding patient-centered cancer care models.

📑 NOTABLE PUBLICATIONS

"Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress"

Authors: M Yang, D Shi, J Lyu, Y Pan, Y Lyv, X Chen, Y Ouyang, Y Liu, Y Li, L Song
Journal: Redox Biology
Year: 2025

"X-ray-activated nanoscintillators integrated with tumor-associated neutrophils polarization for improved radiotherapy in metastatic colorectal cancer"

Authors: H Li, J Zeng, Q You, M Zhang, Y Shi, X Yang, W Gu, Y Liu, N Hu, Y Wang, X Chen, J Mu
Journal: Biomaterials
Year: 2025

Yusheng Liu | Interventional Cardiology | Best Researcher Award 

Posted on by Cardiology and Cardiovascular Medicine

Prof. Yusheng Liu | Interventional Cardiology | Best Researcher Award

The Second Hospital of Shandong University | China

Author Profile:

Scopus

🩺 PROF. YUSHENG LIU – A PIONEER IN HEART FAILURE & ECHOCARDIOGRAPHY

🎓 EARLY ACADEMIC PURSUITS

Prof. Yusheng Liu began his illustrious academic journey in Clinical Medicine at Taishan Medical School (now The First Medical University of Shandong), earning his Bachelor’s degree (1995–2000). His quest for deeper knowledge led him to pursue a Master’s degree in Internal Medicine with a focus on Cardiovascular Disease at Shandong University School of Medicine (2004–2007), followed by an M.D. in Cardiovascular Medicine (2010–2013) from the same institution.

👨‍⚕️ PROFESSIONAL ENDEAVORS

Since July 2000, Prof. Liu has served at the Second Hospital of Shandong University, currently holding the title of Deputy Chief Physician of Cardiovascular Medicine, Associate Professor, and Doctoral Supervisor. He also leads the Cardiac Care Unit (CCU) and plays a pivotal role in guiding the next generation of clinicians as a Master’s tutor.

His career also extends into professional societies, where he holds several leadership roles, including:

  • Executive Director, China Ultrasonic Medical Engineering Society (Echocardiography Division)

  • Vice Chairman, Shandong Ultrasound in Medicine Engineering Institute

  • Youth Leader, Shandong Medical Health System

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON INTERVENTIONAL CARDIOLOGY

Prof. Liu has dedicated his research to heart failure, echocardiography, coronary artery disease, and atherosclerosis. He has:

  • Led or contributed to multiple National Key Projects such as 973, 863, and the National Natural Science Foundation

  • Chaired international collaborations like the Macau SAR Science & Technology Fund

  • Focused heavily on biomarker-based diagnostics, ventricular function in diabetes, and plaque stability in coronary syndromes

His projects have bridged clinical and basic science, contributing to real-world patient improvements and high-impact academic knowledge.

🏆 IMPACT AND INFLUENCE

Prof. Liu’s work has been nationally and internationally recognized:

  • Two-time winner of National Science and Technology Progress Award

  • Recipient of multiple provincial awards including 4 second-place and 6 third-place Science & Tech Awards

  • Frequent keynote speaker at conferences such as:

    • 24th Great Wall International Cardiology Conference

    • 12th National Echo Cardiac Conference

    • 2016 Pharmacology & Ethnopharmacology Conference, Chicago, USA

He is also involved in clinical ethics, oncology cardiology, heart rehabilitation, and hypertension professional committees.

📚 ACADEMIC CITATIONS AND MEMBERSHIPS

Prof. Liu is a proud member of:

  • American Society of Echocardiography (ASE)

  • China Ultrasound Medical Engineering Society (Permanent Member)

  • Various Shandong Medical Associations across cardiology, ethics, and disaster medicine

His publications and research are cited in numerous national and international cardiovascular journals and conferences, further amplifying his impact on the global stage.

🧪 SCIENTIFIC PROJECTS (SELECTED)

Some of the noteworthy research projects under his leadership include:

  1. Huatong-Guokang Medical Scientific Research Project – Ministry of Education (2023)

  2. Clinical Elite Scientist Programme (2018)

  3. National Key R&D Plan (2022YFC3502100)

  4. Lipoprotein-Associated Phospholipase A2 and Plaque Stability (2014)

  5. JNK Pathway and Atherosclerosis Mechanism (2013)

  6. DPP-4 Inhibitors and Ventricular Function in Diabetic Patients (2013)

🏅 AWARDS AND HONORS

Prof. Liu has received:

  • Lecture Honorary Certificate – Pharmacology & Ethnopharmacology 2016

  • Shandong Soft Science Excellence Award

  • Outstanding Teaching Certificate – Weifang University (2016)

  • Advanced Medical Worker Honor – Phoenix Media

  • Scholarships from Shandong University and affiliated hospitals

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Prof. Yusheng Liu stands as a leading voice in the evolution of cardiovascular care in China and beyond. His multidisciplinary influence spans clinical excellence, scientific innovation, academic mentorship, and global collaboration.

In the years to come, his focus on integrating precision medicine, biomarkers, and advanced imaging will continue shaping the future of heart failure diagnostics, ultrasound cardiology, and clinical translational research. With a legacy rooted in innovation and education, he continues to inspire and uplift the cardiovascular medicine community.

📑 NOTABLE PUBLICATION

"Analysis of Platelet Morphological Parameters as Clinical Risk Stratification in Acute Coronary Syndrome"

Authors: Xuguang Zhang, Zhiwei Huang, Xin Wang, Han Hao, Dali Fan, Martin Cadeiras, Yusheng Liu
Journal: Catheterization and Cardiovascular Interventions
Year: 2025

 

Zhiqi Zhao | Echocardiogram | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Ms. Zhiqi Zhao | Echocardiogram | Best Researcher Award

The Second XIANGYA Hospital Of Central South University | China

Author Profile: 

Scopus

🌟 BIOGRAPHY OF MS. ZHIQI ZHAO: A RISING STAR IN RESPIRATORY MEDICINE AND CLINICAL RESEARCH

🎓 EARLY ACADEMIC PURSUITS

Ms. Zhiqi Zhao began her academic journey in medicine at the Xiangya School of Medicine, Central South University, where she was enrolled in the prestigious 8-year Clinical Medicine Program from September 2016 to June 2022. Throughout her undergraduate years, she distinguished herself through her academic excellence and research enthusiasm. She was awarded the Central South University Xinmiao Award and successfully led a National College Student Innovation and Entrepreneurship Project, while participating in two other innovation projects (one national, one university-level).

Her early clinical exposure came through clerkships in internal medicine, surgery, gynecology, and pediatrics, conducted at the renowned Xiangya Second Hospital. This period laid a strong foundation for her future medical and research endeavors.

🏥 PROFESSIONAL ENDEAVORS

Currently, Ms. Zhao is a Ph.D. Candidate in Pulmonary and Critical Care Medicine at Xiangya Hospital Second Affiliated to Central South University, a role she has held since September 2022. Her GPA of 3.70/4.0 reflects her dedication and aptitude in a highly demanding field.

She has successfully completed rigorous clinical rotations across departments including internal medicine, surgery, gynecology, pediatrics, diagnostics, and other key support specialties. In addition, she has passed both the Practical and Written Physician Qualification Exams in China (2023), demonstrating her readiness for professional clinical responsibilities.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ECHOCARDIOGRAM

Ms. Zhao’s research career is marked by significant contributions to chronic respiratory diseases, especially Chronic Obstructive Pulmonary Disease (COPD) and asthma, and the impact of corticosteroids and tobacco exposure on disease outcomes.

Her Ph.D. research includes a pivotal role in the Hunan Natural Science Foundation project titled:
🔬 "Mechanism by which Early-Life Tobacco Exposure Contributes to COPD via AQP1 Methylation Inhibiting HIF-2α / VEGF-A / RA Signaling Pathway" (Project No. 2023JJ30742), under the leadership of PI Dr. Huihui Zeng.

She has also participated in poster presentations such as the 21st National Conference on Clinical Epidemiology and Evidence-Based Medicine, where her work on corticosteroid impact on COPD mortality gained recognition.

📄 IMPACT AND INFLUENCE THROUGH PUBLICATIONS

Ms. Zhao is a co-author of several high-impact journal publications, including:

  • Redox Biology (IF = 11.40, JCR Q1): Research on TET2 deficiency and ferroptosis in COPD.

  • Journal of General Internal Medicine (IF = 5.70, JCR Q1): Focused on inhaled medication adherence in Chinese COPD patients.

  • Frontiers in Medicine (IF = 5.09, JCR Q2): Comparing asthma and COPD patient responses during the COVID-19 pandemic.

  • Scientific Reports (IF = 4.60, JCR Q2): AECOPD treatment efficacy with Nemonoxacin vs. Moxifloxacin.

These contributions not only underscore her expertise but also highlight her commitment to evidence-based medicine and improving patient outcomes.

🧠 ACADEMIC CITES AND SCHOLARSHIP

Ms. Zhao has been consistently recognized for her academic achievements, including:

🏅 Graduate Academic Scholarship (Second Prize – twice, Third Prize – once)
📌 Presenter at a national academic conference
📚 Contributor to studies currently under peer review, indicating ongoing research momentum

Her published works are cited in high-tier journals, reflecting scholarly impact in respiratory and internal medicine communities.

💻 TECHNICAL PROFICIENCIES

Ms. Zhao is adept in a wide array of research and analytical tools, including:

  • Statistical & Bioinformatics Tools: R, SPSS, FlowJo, GraphPad Prism, ImageJ

  • Document & Reference Management: EndNote, Adobe Acrobat

  • Media & Communication Tools: Photoshop, Premiere

  • Daily Office Work: Word, Excel, PowerPoint

These proficiencies allow her to manage and analyze complex clinical data efficiently and to present her findings in impactful ways.

💬 LANGUAGE & COMMUNICATION

📘 English Proficiency: Passed CET-6
Her ability to communicate scientific findings effectively in both Chinese and English enhances her global research collaboration potential.

💫 LEGACY AND FUTURE CONTRIBUTIONS

Ms. Zhao stands out not only for her current achievements but also for her vision and adaptability. She brings a unique blend of clinical insight, research acumen, and passion for discovery. With her expanding portfolio of published work, active participation in national-level projects, and a strong academic background, she is poised to make transformative contributions to pulmonary medicine and global respiratory health.

Her legacy, even in these early years, is that of a committed scholar-practitioner bridging research and real-world impact, and her future undoubtedly holds promise in both academic medicine and clinical innovation.

📑NOTABLE PUBLICATIONS

"Early smoking lead to worse prognosis of COPD patients: a real world study"

Authors: Wu, J., Meng, W., Ma, Y., Zhao, Z., Xiong, R., Wang, J., Zhao, R., Zeng, H., Chen, Y.
Journal: Respiratory Research
Year: 2024

"Suboptimal peak inspiratory flow rate: a noticeable risk factor for inhaler concordance in patients with chronic airway diseases"

Authors: Meng, W., Xiong, R., Zhao, Z., Zeng, H., Chen, Y.
Journal: BMJ Open Respiratory Research
Year: 2024

Chenliang Ge | Cardio-oncology | Best Research Article Award

Posted on by Cardiology and Cardiovascular Medicine

Mr. Chenliang Ge | Cardio-oncology | Best Research Article Award

The First Affiliated Hospital of Guangxi Medical University | China

Author Profile:

Scopus

Orcid

🫀DR. CHENLIANG GE, MD, PHD – A PIONEERING CARDIOVASCULAR RESEARCHER & CLINICIAN

Dr. Chenliang Ge is an accomplished physician-scientist whose work bridges clinical cardiology and data-driven medical research. With a robust foundation in both molecular mechanisms and large-scale epidemiological analysis, he continues to redefine the frontiers of cardiovascular science and patient care.

🎓 EARLY ACADEMIC PURSUITS

Dr. Ge began his academic journey with a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Nanhua University, Hengyang (2008–2013). His passion for cardiology led him to pursue a Master of Science in Cardiology (2013–2016) from the same university. Advancing his specialization, he earned a PhD in Cardiology from Guangxi Medical University, Nanning, China (2019–2022), where he laid the groundwork for his breakthrough research in atrial fibrillation and molecular cardiology.

👨‍⚕️ PROFESSIONAL ENDEAVORS

Since 2016, Dr. Ge has served as an Attending Physician at the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. In this role, he:

  • Diagnoses and manages complex cardiovascular conditions.

  • Specializes in radiofrequency ablation procedures for atrial fibrillation (AF) and supraventricular tachycardia.

  • Combines clinical acumen with cutting-edge research to enhance patient outcomes.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIO-ONCOLOGY

Dr. Ge’s research interests lie at the confluence of cardiology, artificial intelligence, and epidemiology. His contributions span three major domains:

1. EPIDEMIOLOGICAL INSIGHTS INTO CVD AND SYSTEMIC HEALTH

  • Cardiovascular Disease and Cancer Mortality (2024): Identified heart failure as a standalone risk factor for cancer mortality using NHANES data.

  • Physical Activity in Hypertension (2024): Demonstrated the life-extending benefits of moderate-intensity exercise in hypertensive patients.

2. MOLECULAR MECHANISMS IN ARRHYTHMIAS

  • PhD Dissertation: Uncovered the role of TLR4 and NLRP3 inflammasome activation in atrial fibrillation.

  • Key Finding (2022): TLR4 silencing reduced atrial fibrosis and AF susceptibility by downregulating NLRP3-TGF-β pathways, suggesting promising therapeutic targets.

3. TECHNOLOGY-DRIVEN DIAGNOSIS AND PROGNOSIS

  • Echocardiographic Risk Stratification (2024): Developed an automated tool using echocardiography to predict left atrial low-voltage areas (LA-LVAs).

  • Gene Signature for NIDCM Prognosis (2020): Created a two-gene model to predict survival and ventricular arrhythmias in non-ischemic dilated cardiomyopathy (NIDCM).

🧠 TECHNICAL AND CLINICAL EXPERTISE

RESEARCH SKILLS:

  • Molecular biology techniques: PCR, Western blotting, immunohistochemistry.

  • Confocal microscopy and in vivo/in vitro models.

  • Epidemiological analysis using NHANES and UK Biobank datasets.

  • Data analytics: Python, R, SPSS; Machine learning and deep learning.

CLINICAL EXPERTISE:

  • Cardiac electrophysiology and ablation procedures.

  • Echocardiography with tools like Philips Epic 7C and AutoStrain.

  • Risk modeling and survival analysis for personalized cardiac care.

🌍 IMPACT AND INFLUENCE

Dr. Ge's work directly informs both clinical practice and public health policy. By connecting chronic diseases like heart failure and cancer, his findings push for integrated healthcare models. His gene-based and imaging-based diagnostic tools enable precision medicine, allowing for personalized and cost-effective interventions.

📚 ACADEMIC CITES

  • Ge et al., 2020 – Gene Signature in NIDCM

  • Ge et al., 2022 – TLR4 & NLRP3 in Atrial Fibrillation

  • Ge et al., 2024 – Physical Activity in Hypertension & CVD-Cancer Link

  • Chang et al., 2024 – Echocardiographic Risk Stratification (collaborative work)

🚀 LEGACY AND FUTURE CONTRIBUTIONS

With a unique blend of clinical insight and computational proficiency, Dr. Ge is at the forefront of next-generation cardiovascular care. His future directions likely include:

  • Expanding the use of AI in cardiology diagnostics.

  • Further investigating multi-system interactions in chronic diseases.

  • Advocating for preventive cardiology through large-scale data and public health outreach.

His legacy is one of bridging bench-to-bedside translation, ensuring that rigorous research translates into better lives for patients globally.

📑 NOTABLE PUBLICATIONS

"The global burden of high BMI among adolescents between 1990 and 2021" 

Authors: Ge C; Xiong J; Zhu R; Hong Z; Yan He
Journal: Communications medicine
Year: 2025

"Automatic Echocardiographic Assessment of Left Atrial Function for Prediction of Low-Voltage Areas in Non-Valvular Atrial Fibrillation" 

Authors: Shuai Chang; Xiaofeng Zhang; Chenliang Ge; Yanfen Zhong; Decai Zeng; Yongzhi Cai; Tongtong
Journal: International Journal of General Medicine
Year: 2024

"Associations between cardiovascular diseases and cancer mortality: insights from a retrospective cohort analysis of NHANES data" 

Authors: Ge C; Jiang Z; Long B; Lu Q; He Y
Journal: BMC public health
Year: 2024

Cheng Shen | Cardiac Surgery | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Cheng Shen | Cardiac Surgery | Best Researcher Award

West China Hospital | China

Author Profile: 

Scopus

Orcid

📘 EARLY ACADEMIC PURSUITS 

Cheng Shen began his academic journey at Kunming Medical University, earning his Bachelor of Medicine in Clinical Medicine in 2011. His passion for clinical excellence and research led him to the West China School of Medicine, Sichuan University, where he pursued a Ph.D. in Thoracic Surgery while simultaneously working as a Resident Doctor and Research Assistant from 2011 to 2017. During this period, he honed his clinical and research acumen, laying a strong foundation for his future contributions to oncology and thoracic surgery.

🩺 PROFESSIONAL ENDEAVORS

Dr. Cheng Shen currently serves as an Attending Physician in the Department of Thoracic Surgery at West China Hospital, Sichuan University. His international academic exposure includes his time as a Visiting Scholar at Yale University (2015–2016) in the Department of Molecular Biophysics and Biochemistry, where he advanced his expertise in molecular mechanisms of DNA repair. This blend of clinical practice and laboratory precision has equipped him to lead cutting-edge investigations in thoracic oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC SURGERY

Dr. Shen’s research spans several high-impact domains, including:

  • Targeted Gene Therapy and Immunotherapy

  • Molecular Mechanisms of Cancer Invasion and Metastasis

  • Cell and Tissue Engineering

  • Stem Cell Function and Differentiation

His research during his Yale tenure focused on the mechanism of homology-directed DNA repair, using yeast and human models. He also explored genomic instability in primary lung cancers and conducted studies on cancer-associated fibroblasts in lung adenocarcinoma.

🌐 IMPACT AND INFLUENCE 

Cheng Shen has contributed significantly to the understanding of tumor biology, particularly in thoracic malignancies. His ability to translate complex molecular biology into practical clinical insights makes him a crucial figure in personalized cancer therapy. He has also designed and led several small clinical trials, emphasizing his commitment to bridging the bench-to-bedside gap.

🏅 ACADEMIC CITES AND COLLABORATIONS

While specific citation counts are not provided, his training at Yale University, multiple national-level scholarships, and leadership in clinical trials reflect a robust academic profile. His research work is likely referenced in the fields of genomic instability, lung cancer, and DNA repair mechanisms.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Cheng Shen’s future appears poised for further breakthroughs in thoracic cancer treatment and regenerative medicine. As a physician-scientist with deep laboratory roots and clinical experience, he is uniquely positioned to drive innovation in cancer therapy, particularly with emerging gene and cell-based interventions. His trajectory indicates continued leadership in integrative and translational medical research.

🏆 OTHER IMPORTANT AREAS OF EXCELLENCE 

LANGUAGE PROFICIENCY:

  • Advanced in English, having cleared PETS-3, PETS-4, CET-4, and CET-6.

LAB PROFICIENCY:

  • Expertise in PCR, Western Blot, ELISA, Cell Culture, and Signaling Pathway Inhibition.

  • Strong in Animal Models and Transwell Cell Migration assays.

HONORS & SCHOLARSHIPS:

  • State Scholarship Fund (CSC) (2015–2017)

  • National Graduate Scholarships (2012–2014)

  • Full Scholarship from Sichuan University (2011–2016)

  • Multiple Merit Scholarships during undergraduate studies

NOTABLE PUBLICATIONS

"Accuracy of Large Language Models for Literature Screening in Thoracic Surgery: Diagnostic Study"

Authors: ZY Dai, FQ Wang, C Shen, YL Ji, ZY Li, Y Wang, Q Pu
Journal: Journal of Medical Internet Research
Year: 2025

"A combined subsegmentectomy of right S9 + 10b with single direction thoracoscopic surgery"

Authors: C Shen, C Liu
Journal: Journal of Cardiothoracic Surgery
Year: 2024

"Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta-analysis"

Authors: Shen C, Li J, Li J, Che G
Journal: Thoracic Cancer
Year: 2022

Shuai Wang | Ischemic Stroke | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Mr. Shuai Wang | Ischemic Stroke | Best Researcher Award

Royal College of Surgeons | Ireland

Author Profile:

Scopus

Orcid

🎓 EARLY ACADEMIC PURSUITS

Shuai Wang began his academic journey in the field of pharmacy at Soochow University in Suzhou, Jiangsu Province. He earned his Bachelor of Pharmacy (2015–2019) and continued there for a Master’s degree in Pharmacy (2020–2023). His consistent academic excellence led him to pursue a PhD in Pharmacy at the Royal College of Surgeons in Ireland (2023–Present). His early dedication to the sciences laid the groundwork for a promising career in neuropharmacology.

🧪 PROFESSIONAL ENDEAVORS 

During his time at Soochow University, Shuai Wang was actively involved in numerous cutting-edge research projects under the guidance of Professor Hui-Ling Zhang. His work primarily focused on the molecular mechanisms underlying ischemic stroke and neuroinflammation, combining both in vivo and in vitro methodologies to produce meaningful scientific insights.

He contributed significantly to interdisciplinary research through collaborative pharmacodynamic studies, including:

  • DTIO’s role in promoting brain function recovery post-stroke (2021–2022)

  • VT101’s protective effects against myocardial ischemia/reperfusion injury (2020–2021)

🧬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC STROKE

Wang’s research focus is neuropharmacology, with an emphasis on neuroinflammation, lipid metabolism, and cellular cross-talk following ischemic stroke. One of his landmark projects investigated the VEGFD/VEGFR3 pathway and its regulatory effect on IL-3/IL-3Rα interactions between astrocytes and microglia. His innovative approach used metabolic analysis and dual-model experimentation to explore cellular responses and pharmacological mechanisms.

📈 IMPACT AND INFLUENCE 

Shuai Wang has co-authored influential research papers in high-impact journals, including:

  • VEGFD/VEGFR3 mediates neuroinflammation and lipid metabolism reprogramming after ischemic stroke by regulating IL-3/IL-3Rα crosstalk between astrocytes and microglia.

  • The novel role and anti-inflammatory mechanisms of brain matrilin-3 in ischemic stroke, published in Cell Reports alongside distinguished co-authors.

These publications reflect his deep engagement with pressing medical challenges and his ability to contribute meaningfully to collaborative scientific inquiry.

🏅 ACADEMIC CITES AND RECOGNITIONS 

Wang's academic work has begun to garner citations and recognition within pharmacological and neuroscience communities. In recognition of his academic diligence and research output, he was awarded the Soochow University Master Scholarship consecutively in 2020, 2021, and 2022.

🚀 LEGACY AND FUTURE CONTRIBUTIONS 

Shuai Wang represents the next generation of innovative scientists in the field of neuropharmacology. With a strong academic foundation, extensive research training, and a visionary approach to disease mechanisms and treatment development, he is well-positioned to make future breakthroughs in stroke therapy and neurodegenerative disease research.

As he continues his doctoral research in Ireland, his future contributions are anticipated to shape both the theoretical landscape and clinical applications in neurology and pharmacotherapy.

📑 NOTABLE PUBLICATIONS

"VEGFD/VEGFR3 signaling contributes to the dysfunction of the astrocyte IL-3/microglia IL-3Rα cross-talk and drives neuroinflammation in mouse ischemic stroke"

Authors: Shuai Wang; Yi Guo; Rui-qi Cao; Yong-ming Zhu; Shi-gang Qiao; Hua-ping Du; Yuan Liu; Yuan Xu; Xian-yong Zhou; Lei Sun
Journal: Acta Pharmacologica Sinica
Year: 2025

 

Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Mr. Di-Hua Yu | Cardiopulmonary Resuscitation | Best Researcher Award

Hubei Provincial Hospital of TCM | China

Author Profile:

Orcid

🎓 EARLY ACADEMIC PURSUITS

Di-Hua Yu laid a solid foundation for his medical and research career at the Hubei University of Chinese Medicine. He earned his Bachelor’s degree (2007–2012) with a stellar GPA of 3.9/4.0, receiving the prestigious First Prize Scholarship 🏅. He continued his academic excellence in his Master’s program (2012–2014), graduating with a GPA of 3.8/4.0 and being named an Outstanding Graduate 🌟. These early achievements highlighted his strong work ethic, deep curiosity, and aptitude for medical research.

💼 PROFESSIONAL ENDEAVORS

Since 2014, Yu has served as a Researcher in the Emergency Department at the Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 🇨🇳. His role places him at the heart of real-time emergency care, where he applies both traditional Chinese medical knowledge and modern evidence-based practices. His daily work bridges front-line clinical challenges and academic inquiry 📊🩺.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOPULMONARY RESUSCITATION

Yu’s research spans a multidisciplinary range of subjects that combine innovation with tradition:

  • 🏥 Emergency Medical Systems

  • ❤️ Cardiopulmonary Resuscitation

  • 💔 Cardiac Arrest

  • 📈 Statistical Analysis

  • 🤖 Artificial Intelligence in Medicine

His work reflects an evolving research focus that responds to modern healthcare challenges while respecting the insights of traditional Chinese medicine 🧪🌿.

🌐 IMPACT AND INFLUENCE

Di-Hua Yu has made meaningful scholarly contributions through publications such as:

  • “Factors Influencing Resuscitation Outcomes in Obese Out-of-Hospital Cardiac Arrest Patients” – Notfall + Rettungsmedizin 🚨

  • “Research Progress on the Toxicity of Tripterygium Wilfordii and Attenuated Synergistic Approaches” – YIXUE ZONGSHU

  • Multiple clinical studies on integrative therapies using Chinese herbal injections and formulations 🌱💉

These studies provide valuable insights into treatment effectiveness, especially in high-risk or emergency scenarios.

📚 ACADEMIC CITES

Yu’s ORCID profile (🔗 0000-0001-8628-4005) serves as his official research ID. While his presence on global platforms like Google Scholar and ResearchGate is still in development, the quality and diversity of his publications suggest growing academic recognition and future citation potential 📖✨.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Di-Hua Yu stands out as a forward-thinking medical researcher who blends traditional Eastern practices with modern Western methodologies. With rising global interest in AI-driven medical support systems 🤖 and personalized emergency care, Yu is well-positioned to contribute to:

  • 📡 Smarter Emergency Response Systems

  • 🔍 Data-Based Clinical Decision Tools

  • 🧬 Personalized Resuscitation Strategies

  • 🌏 Global Dialogues on Integrative Medicine

His legacy is expected to lie in fostering collaboration between ancient healing philosophies and next-generation technology 🛠️🌿.

📑NOTABLE PUBLICATIONS

"Factors influencing resuscitation outcomes in obese out-of-hospital cardiac arrest patients"

Authors: Wei-Qing Wang, Ying-Lin Wang, Zheng Zhu, Xiao-Xia Zeng, Gang Li, Di-Hua Yu
Journal: Notfall + Rettungsmedizin
Year: 2025

 

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Hadi Emamat | Body Fat Distribution | Best Researcher Award

Bushehr University of Medical Sciences | Iran

Author Profile:

🎓 EARLY ACADEMIC PURSUITS

Dr. S.M. Hadi Emamat began his academic journey in the field of Nutrition Sciences at Shahid Beheshti University of Medical Sciences (SBMU), one of Iran's premier institutions. He completed his Bachelor's degree (2007–2011), followed by a Master's (2012–2015) and eventually earned his Ph.D. (2016–2020) in the same field. From the outset, Dr. Emamat demonstrated a strong commitment to exploring how diet influences health and disease, particularly focusing on metabolic and liver conditions.

👨‍🏫 PROFESSIONAL ENDEAVORS

Dr. Emamat currently serves as an Assistant Professor at the Department of Nutritional Sciences, School of Health and Nutrition, Bushehr University of Medical Sciences (BPUMS), Iran. His role encompasses both academic teaching and active research. He imparts knowledge through specialized courses, notably Medical Nutrition Therapy, aiming to train the next generation of nutrition professionals.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON BODY FAT DISTRIBUTION

Dr. Emamat's scientific research is primarily centered on the relationship between nutrition and chronic metabolic disorders. His scholarly work includes:

  • Investigating barberry's effect on cardiovascular risk factors in hypertensive patients for his Ph.D. thesis.

  • Studying the impact of onion consumption on features of nonalcoholic fatty liver disease (NAFLD) in animal models during his Master's research.

His broader research interests include:

  • Nutrition and Non-Alcoholic Fatty Liver Disease (NAFLD)

  • Nutrition and Cardiovascular Disease, particularly vascular function

  • Metabolic Syndrome

  • Nutrition and Gut Microbiota

These studies contribute to a growing body of evidence linking diet with systemic inflammation, blood pressure regulation, lipid profiles, and metabolic health.

🌍 IMPACT AND INFLUENCE

Dr. Emamat's work addresses global public health challenges, such as cardiovascular disease and NAFLD, which are on the rise due to poor dietary habits and sedentary lifestyles. His research provides valuable insights into how traditional foods and natural compounds can serve as functional interventions for chronic conditions. As an educator and investigator, he plays a pivotal role in shaping clinical nutrition strategies in Iran and beyond.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

With a solid foundation in clinical nutrition research and education, Dr. Emamat is well-positioned to make further advances in nutritional interventions for chronic diseases. His continued focus on evidence-based dietary solutions, integration of microbiome science, and public health applications will likely shape both policy and practice in the years ahead. His dedication signals a promising trajectory toward becoming a key figure in translational nutrition science.

📑 NOTABLE PUBLICATIONS

"The association between the visceral to subcutaneous abdominal fat ratio and the risk of cardiovascular diseases: a systematic review" 

Authors: Hadi Emamat, Ali Jamshidi, Akram Farhadi, Hamid Ghalandari, Mohadeseh Ghasemi, Hadith Tangestani
Journal: BMC public health
Year: 2024

"Association of serum 25-hydroxy vitamin D status with cardiometabolic risk factors and total and regional obesity in southern Iran: evidence from the PoCOsteo study" 

Authors: Alireza Nejabat, Hadi Emamat, Sima Afrashteh, Ali Jamshidi, Zahra Jamali, Akram Farhadi, Zahra Talkhabi, Iraj Nabipour, Bagher Larijani, Jörg Spitz
Journal: Scientific Reports
Year: 2024

Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Yuriy Borshchev | Ischemic-reperfusion injury | Best Researcher Award

Almazov National Medical Research Center | Russia

Author Profile:

Scopus

Orcid

🏅 BEST RESEARCHER PROFILE: DR. YURIY BORSHCHEV

👨‍🎓 EARLY ACADEMIC PURSUITS

Dr. Yuriy Borshchev was born on April 13, 1968, in Chisinau, Republic of Moldova. His academic journey began at Chisinau State University, where he pursued his studies from 1985 to 1992 in the Faculty of Biology and Soil Science, majoring in Biology with a specialization in Human and Animal Physiology. This foundational education laid the groundwork for his future contributions to physiological and biomedical research.

💼 PROFESSIONAL ENDEAVORS

Before fully immersing himself in academia, Dr. Borshchev gained extensive practical experience in various industries. Between 1992 and 2007, he worked in mechanical engineering and food processing enterprises in Moldova, advancing from logistics roles to leadership positions such as enterprise director. In 2007, he transitioned into scientific research, joining the Pavlov Institute of Animal Physiology as a laboratory assistant and later as a research associate.

By 2012, he earned his PhD (Candidate of Biological Sciences) with a dissertation focused on the effects of probiotic bacteria on intestinal enzymes in rats with dysbiosis. His career progressed as he became a senior researcher at the Institute of Experimental Medicine and, later, the Almazov National Medical Research Center, where he now serves as Head of the Physiological Microendoecology Department.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ISCHEMIC-REPERFUSION INJURY

Dr. Borshchev's work sits at the intersection of cardiology, gastroenterology, microbiology, and pathophysiology. His key contributions include:

  • Development of novel experimental biomedical models for studying inflammation and metabolic disorders.

  • Creation of a systemic inflammatory response model in rats, used to evaluate the therapeutic potential of probiotic bacteria.

  • Pioneering research into the influence of intestinal microbiota on myocardial resistance to ischemia-reperfusion injury.

  • Broad expertise in biochemical, histological, microbiological, and behavioral methodologies, as well as surgical experimentation on lab animals.

🌍 IMPACT AND INFLUENCE

Dr. Borshchev has significantly contributed to experimental medicine through:

  • Over 70 scientific publications, including 40 in SCI/SCIE journals and 18 indexed in Scopus/Web of Science/PubMed.

  • An H-index of 5, with a citation count of 22, reflecting ongoing recognition in specialized fields.

  • 8 completed research projects and 2 ongoing, amounting to over $800,000 USD in funding.

  • 5 industry-sponsored consultancy projects, demonstrating applied research impact.

  • Author and contributor to 8 books and proceedings with ISBNs.

  • One patent published, highlighting innovation in translational medical science.

📚 ACADEMIC CITES AND LEADERSHIP

In his academic and professional capacity, Dr. Borshchev:

  • Has served in editorial and reviewer roles for 2 journals/conferences.

  • Delivered 4 invited talks, attended 15 conferences, and visited 4 countries for international collaboration.

  • Supervised and graduated 2 research scholars, and is actively involved in collaborative scientific projects.

  • Maintains active profiles in global databases:

    • Scopus Author ID: 57206730176

    • Web of Science Researcher ID: IDE-1363-2014

    • elibrary.ru SPIN-code: 3454-4113

🧪 LEGACY AND FUTURE CONTRIBUTIONS

As a leading scientist at the Almazov National Medical Research Center, Dr. Borshchev continues to push the boundaries of experimental and translational medicine. His legacy is built on:

  • Bridging microbial ecology and systemic physiology.

  • Advancing knowledge in cardio-gastrointestinal interactions.

  • Training the next generation of scientists and building collaborative international partnerships.

Looking forward, Dr. Borshchev aims to expand his department's work into oncopharmacology and metabolic disease modeling, with the potential to influence both clinical therapies and preclinical standards.

🏆 AWARDS AND PROFESSIONAL AFFILIATIONS

Dr. Borshchev has been honored with 4 research awards, and holds 2 professional body memberships. He is committed to ethical research, demonstrated by his GLP-certified training in preclinical study protocols and laboratory animal handling.

🤝 COLLABORATIONS AND NETWORKING

  • 2 active MoUs with universities/industries.

  • 2 joint collaborative publications/projects.

  • Contributed to scientific communities across Russia, Europe, and other research-focused regions.

📌 CONCLUSION

Dr. Yuriy Borshchev exemplifies the qualities of a Best Researcher Award recipient: innovative, dedicated, and globally engaged. His work stands out for its relevance, depth, and potential to influence medical science well into the future.

📑 NOTABLE PUBLICATIONS

"Brain-Derived Neurotrophic Factor Cancels the Cardioprotective Effect of Interleukin-2 in a Model of Systemic Inflammatory Response in Rats"

Authors: I.Y., Burovenko, Inessa Yu , Y.Y., Borshchev, Yury Yu , S.M., Minasyan, Svetlana M. , ... O.V., Borshcheva, Olga V. , M.M., Galagudza, Mikhail M.
Journal: Bulletin of Experimental Biology and Medicine
Year: 2025

"Changes in the activity of amylase, alkaline phosphatase and lipase in placenta and umbilical cord blood in women in labor with gestational diabetes mellitus"

Authors: Elena V. Kolodkina; Sergey A. Lytaev; Michael M. Galagudza; Alexander B. Loginov; Tatyana M. Pervunina; Stanislav I. Sitkin; Yuri Yu. Borschchev; Olga V. Borschcheva
Journal: Medical academic journal
Year: 2025

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

Posted on by Cardiology and Cardiovascular Medicine

Fengxu Yu | Atrial Fibrillation | Best Researcher Award 

The Affiliated Hospital of Southwest Medical University | China

Author Profile:

Scopus

👨‍⚕️ MR. FENGXU YU – PIONEER IN CARDIOVASCULAR INNOVATION

🎓 EARLY ACADEMIC PURSUITS

Born in January 1976, Professor Fengxu Yu embarked on his medical journey with a strong academic foundation, earning his M.D. and later achieving qualifications as a doctoral supervisor. His passion for cardiovascular science led him to pursue postdoctoral training in France, equipping him with a global perspective and refined clinical research skills. This international exposure laid the groundwork for his future leadership in complex cardiovascular research and surgical practice.

💼 PROFESSIONAL ENDEAVORS

Currently serving as a Professor at The Affiliated Hospital of Southwest Medical University, Dr. Yu holds several distinguished roles:

  • Standing Committee Member, Cardiac Surgery Committee (CAMEA)

  • Committee Member, Heart Valve Committee (CRHA)

  • Vice Chair, Sichuan Thoracic & Cardiac Surgery Association

  • Academic Leader, recognized by the Sichuan Health Commission

  • Member, Asian Heart Valve Society, China Chapter

  • Recipient, Luzhou Top Talent Award

His consistent dedication has cemented his role as a leading figure in thoracic and cardiac surgery across China.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON ATRIAL FIBRILLATION

Dr. Yu’s research endeavors focus on molecular and biomechanical mechanisms in cardiovascular disease, especially atrial fibrillation (AF), atherosclerosis, and aortic dissection. His current areas of exploration include:

  • Non-coding RNAs (e.g., circRNA/ceRNA networks) in AF pathogenesis

  • Application of induced pluripotent stem cells in modeling AF

  • Effects of shear stress on vascular endothelial health and its link to atherosclerosis

Through these efforts, Dr. Yu bridges basic science with clinical relevance, advancing the future of personalized medicine.

📊 IMPACT AND INFLUENCE

As a principal investigator, Dr. Yu has led nearly 20 major research projects funded by provincial and municipal institutions. He has also contributed to 30+ collaborative studies as a lead or co-investigator. His academic output includes over 50 peer-reviewed publications, with 12 articles indexed in SCI journals and 20+ papers in national core journals, showcasing his thought leadership in cardiovascular science.

📚 SELECTED RESEARCH PROJECTS

Some of Dr. Yu’s notable funded projects include:

  • Mechanism of Shear Stress-Downregulated Annexin A1 (2019)

  • circRNA-Regulated ceRNA Networks in AF (2025)

  • Personalized Warfarin Therapy Post-Valve Replacement (2022)

  • Hsa_circ_0025573—miR-133b—MMP9 in AF Pathogenesis (2022)

  • SRB1-Mediated Endothelial Injury in Atherosclerosis (2018)

These projects reflect a multidisciplinary approach to understanding and treating cardiovascular conditions.

🏅 ACADEMIC CITES AND MEMBERSHIPS

Professor Yu actively contributes to national and international academic bodies. His memberships include:

  • CAMEA – Cardiac Surgery Committee

  • CRHA – Heart Valve Committee

  • Sichuan Thoracic & Cardiac Surgery Association

  • Asian Heart Valve Society – China Chapter

These affiliations enhance his visibility in shaping future cardiac surgery standards and innovations.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Professor Fengxu Yu is a mentor, innovator, and academic leader. His mentorship of graduate students, collaboration with international institutions such as Heidelberg University, and continued work on translational research ensure a legacy of impactful science. As cardiovascular disease remains a global challenge, his pioneering work in non-coding RNA and biomechanical interactions is poised to redefine prevention and treatment strategies.

📑 NOTABLE PUBLICATIONS

"Myocardial infarction serum preconditioning bone marrow mesenchymal stem cell-derived exosomes enhance anti-fibrosis in rat myocardial infarction hearts" 

Authors: Y., Gan, Yang , C., Wang, Changyi , R., Liao, Ruili , ... H., Liu, Hui , Y., Fu, Yong
Journal: Molecular and Cellular Biochemistry.
Year: 2025

"Identification of the optimal reference genes for atrial fibrillation model established by iPSC-derived atrial myocytes" 

Authors: L., Li, Lei , Z., Zhao, Zijuan , Z., Liu, Zihao , ... Y., Nie, Yongmei , F., Yu, Fengxu
Journal: BMC Genomics
Year: 2024

"Postoperative delirium prediction after cardiac surgery using machine learning models" 

Authors: T., Yang, Tan , H., Yang, Hai , Y., Liu, Yan , ... Y., Zhang, Ying , F., Yu, Fengxu
Journal: Computers in Biology and Medicine
Year: 2024